GLP-1s can help reduce appetite and increase fullness signals, but normal hunger should still exist
SeekPeptides members access detailed stacking protocols and personalized guidance for optimizing body composition during GLP-1 therapy
In the free starter map, many meal ideas land around 1025 grams of protein per small meal
In fact, cardiovascular disease represents the leading cause of death for patients with NAFLD.[15], [16] When focussing on liver-related morbidity and mortality, NASH represents the third most common cause of cirrhosis within the United States, but it is predicted to become the leading cause over the next few years.17 NASH cirrhosis is currently the primary aetiology for dual liver-kidney transplantation and is estimated to become the number one indication for liver transplant by 2020.[18], [19], [20] Overall, the distinction between those with NAFLD and those with NASH is clinically relevant given that multiple studies have demonstrated that patients with NASH are at higher risk of adverse liver-related outcomes, with the degree of fibrosis contributing most significantly to this increased risk.[3], [21], [22] The striking prevalence of NAFLD paired with its profound complications underscores the critical need for safe, effective, and broadly applicable therapy
